Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

Acute Rheumatic Fever

  • Author: Robert J Meador, Jr, MD; Chief Editor: Herbert S Diamond, MD  more...
 
Updated: Jul 19, 2016
 

Background

Acute rheumatic fever (ARF) is a sequela of streptococcal infection—typically following two to three weeks after group A streptococcal pharyngitis—that occurs most commonly in children and has rheumatologic, cardiac, and neurologic manifestations. The incidence of ARF has declined in most developed countries, and many physicians have little or no practical experience with the diagnosis and management of this condition. Occasional outbreaks in the United States make complacency a threat to public health.

Diagnosis rests on a combination of clinical manifestations that can develop in relation to group A streptococcal pharyngitis. These include chorea, carditis, subcutaneous nodules, erythema marginatum, and migratory polyarthritis. Because the inciting infection is completely treatable, attention has been refocused on prevention. See the image below.

Clinical manifestations and time course of acute r Clinical manifestations and time course of acute rheumatic fever.
Next

Pathophysiology

Although the inciting bacterial agent is well known, susceptibility factors remain unclear. The location of the streptococcal infection seems to play an important role. The clinical syndrome typically follows a streptococcal pharyngitis, but streptococcal cellulitis has never been implicated.

The earliest and most common feature is a painful migratory arthritis, which is present in approximately 80% of patients. Large joints such as knees, ankles, elbows, or shoulders are typically affected. Sydenham chorea was once a common late-onset clinical manifestation but is now rare.[1] Carditis (with progressive congestive heart failure, a new murmur, or pericarditis) may be the presenting sign of unrecognized past episodes and is the most lethal manifestation.

Genetics may contribute, as evidenced by an increase in family incidence. No significant association with class-I human leukocyte antigens (HLAs) has been found, but an increase in class-II HLA antigens DR2 and DR4 has been found in black and white patients, respectively. Evidence suggests that elevated immune-complex levels in blood samples from patients with ARF are associated with HLA-B5.[2]

In a study of 15 patients with rheumatic heart disease and a control group of 10 patients who had been exposed to group A streptococci but did not develop either acute rheumatic fever or rheumatic heart disease, 13 genes were differentially expressed in the same direction (predominantly decreased) between the two groups. Seven of those were immune response genes involved in cytotoxicity, chemotaxis, and apoptosis. The researchers concluded that the high proportion of differentially expressed apoptotic and immune response genes supports a model of autoimmune and cytokine dysregulation in ARF.[3]

Previous
Next

Etiology

Although the mechanism by which streptococcal organisms cause disease is not entirely clear, overwhelming epidemiologic evidence suggests that ARF is caused by streptococcal infection, and recurrences can be prevented with prophylaxis.

Strains of group A streptococci that are heavily encapsulated and rich in M protein (signifying virulence in streptococcal strains) seem to be most likely to result in infection.

Group A Streptococcus is thought to cause the myriad of clinical diseases in which the host's immunologic response to bacterial antigens cross-react with various target organs in the body, resulting in molecular mimicry. In fact, autoantibodies reactive against the heart have been found in patients with rheumatic carditis. The antibody can cross-react with brain and cardiac antigens, and immune complexes are present in the serum. The problem has been the uncertainty of whether these antibodies are the cause or result of myocardial tissue injury.

Previous
Next

Epidemiology

United States

The incidence of an acute rheumatic episode following streptococcal pharyngitis is 0.5-3%. The peak age is 6-20 years. Although the incidence of ARF has steadily declined, the mortality rate has declined even more steeply. Credit can be attributed to improved sanitation and antibiotic therapy. Several sporadic outbreaks in the United States could not be blamed directly on poor living conditions. New virulent strains are the best explanation.

In Hawaii, the incidence of ARF has remained several times higher than in the continental United States, particularly among ethnic Polynesians. Unusual group A streptococci emm types that are uncommon in the continental United States appear to play a significant role in the epidemiology of ARF in Hawaii.[4]

International

Most major outbreaks occur under conditions of impoverished overcrowding where access to antibiotics is limited. Rheumatic heart disease accounts for 25-50% of all cardiac admissions internationally. Regions of major public health concern include the Middle East, the Indian subcontinent, and some areas of Africa and South America.[5]

As many as 20 million new cases occur each year. The introduction of antibiotics has been associated with a rapid worldwide decline in the incidence of ARF. Now, the incidence is 0.23-1.88 patients per 100,000 population. From 1862-1962, the incidence declined from 250 patients to 100 patients per 100,000 population, primarily in teenagers.

Notably, natives of Polynesian ancestry in Hawaiian and Maori populations are an exception. For example, in a study from a New Zealand district, the ethnicity of ARF patients was 85% Maori and 10% Pacific. Although the annual incidence of ARF was 3.1 per 100,000 population, in with Maori children aged 5-14 years the incidence was 46.1 per 100,000 population. Almost three-quarters of all patients lived in severely socioeconomically deprived areas.[6]

Previous
Next

Mortality/Morbidity

Mortality rates are steadily improving because of better sanitation and health care. The current pattern of morbidity is difficult to measure because the first attack of rheumatic fever follows an unpredictable course. As many as 90% of episodes are clinically contained within 3 months.

Carditis causes the most severe clinical manifestation because heart valves can be permanently damaged. The disorder also can involve the pericardium, myocardium, and the free borders of valve cusps. Death or total disability may occur years after the initial presentation of carditis.

Racial, Sexual, and Age-related Demographics

An association between certain class-II HLA antigens (DR2 in blacks and DR4 in whites) and ARF has been reported.

No general clear-cut sex predilection for ARF has been reported, but certain of its manifestations seem to be sex variable. For example, chorea and tight mitral stenosis occur predominantly in females, while aortic stenosis develops more often in males.

The initial attack of ARF occurs most frequently in persons aged 6-20 years and rarely occurs in persons older than 30 years. The disease may cluster in families. In some countries, a shift into older groups may be a trend.

Previous
 
 
Contributor Information and Disclosures
Author

Robert J Meador, Jr, MD Rheumatologist, Dallas Diagnostic Association

Robert J Meador, Jr, MD is a member of the following medical societies: American College of Physicians-American Society of Internal Medicine, American College of Rheumatology, Texas Medical Association, Dallas County Medical Society, Lupus Foundation of America, Lone Star Chapter, Sjögren’s Syndrome Foundation

Disclosure: Nothing to disclose.

Coauthor(s)

Irwin Jon Russell, MD, PhD, MS, FACR, ACR-Master Medical Director for Fibromyalgia Research and Consulting, (Retired) Faculty, Division of Clinical Immunology and Rheumatology, University of Texas Health Science Center at San Antonio

Irwin Jon Russell, MD, PhD, MS, FACR, ACR-Master is a member of the following medical societies: Alpha Omega Alpha, International Myopain Society, American College of Physicians, American College of Rheumatology, International Association for the Study of Pain

Disclosure: Received consulting fee from Daiichii Sankyo for review panel membership; Received grant/research funds from Pfizer Pharma for independent contractor; Received grant/research funds from Lilly Pharma for independent contractor.

Specialty Editor Board

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Lawrence H Brent, MD Associate Professor of Medicine, Jefferson Medical College of Thomas Jefferson University; Chair, Program Director, Department of Medicine, Division of Rheumatology, Albert Einstein Medical Center

Lawrence H Brent, MD is a member of the following medical societies: American Association for the Advancement of Science, American Association of Immunologists, American College of Physicians, American College of Rheumatology

Disclosure: Serve(d) as a director, officer, partner, employee, advisor, consultant or trustee for: Janssen<br/>Serve(d) as a speaker or a member of a speakers bureau for: Abbvie; Genentech; Pfizer; Questcor.

Chief Editor

Herbert S Diamond, MD Visiting Professor of Medicine, Division of Rheumatology, State University of New York Downstate Medical Center; Chairman Emeritus, Department of Internal Medicine, Western Pennsylvania Hospital

Herbert S Diamond, MD is a member of the following medical societies: Alpha Omega Alpha, American College of Physicians, American College of Rheumatology, American Medical Association, Phi Beta Kappa

Disclosure: Nothing to disclose.

References
  1. Dale RC. Immune-mediated extrapyramidal movement disorders, including Sydenham chorea. Handb Clin Neurol. 2013. 112:1235-41. [Medline].

  2. Yoshinoya S, Pope RM. Detection of immune complexes in acute rheumatic fever and their relationship to HLA-B5. J Clin Invest. 1980 Jan. 65(1):136-45. [Medline].

  3. Bryant PA, Smyth GK, Gooding T, Oshlack A, Harrington Z, Currie B, et al. Susceptibility to acute rheumatic fever based on differential expression of genes involved in cytotoxicity, chemotaxis, and apoptosis. Infect Immun. 2014 Feb. 82(2):753-61. [Medline]. [Full Text].

  4. Erdem G, Mizumoto C, Esaki D, Reddy V, Kurahara D, Yamaga K, et al. Group A streptococcal isolates temporally associated with acute rheumatic fever in Hawaii: differences from the continental United States. Clin Infect Dis. 2007 Aug 1. 45(3):e20-4. [Medline].

  5. Tibazarwa KB, Volmink JA, Mayosi BM. Incidence of acute rheumatic fever in the world: a systematic review of population-based studies. Heart. 2008 Dec. 94(12):1534-40. [Medline].

  6. Pennock V, Bell A, Moxon TA, Reed P, Maxwell F, Lennon D. Retrospective epidemiology of acute rheumatic fever: a 10-year review in the Waikato District Health Board area of New Zealand. N Z Med J. 2014 May 2. 127(1393):26-37. [Medline].

  7. [Guideline] Shulman ST, Bisno AL, Clegg HW, Gerber MA, Kaplan EL, Lee G, et al. Clinical practice guideline for the diagnosis and management of group A streptococcal pharyngitis: 2012 update by the Infectious Diseases Society of America. Clin Infect Dis. 2012 Nov 15. 55(10):e86-102. [Medline].

  8. NINDS Sydenham Chorea Information Page. National Institute of Neurological Disorders and Stroke. Available at http://www.ninds.nih.gov/disorders/sydenham/sydenham.htm. Accessed: December 10, 2104.

  9. Barash J, Mashiach E, Navon-Elkan P, Berkun Y, Harel L, Tauber T, et al. Differentiation of post-streptococcal reactive arthritis from acute rheumatic fever. J Pediatr. 2008 Nov. 153(5):696-9. [Medline].

  10. Jones TD. Diagnosis of rheumatic fever. JAMA. 1944. 126:481-85.

  11. [Guideline] Gewitz MH, Baltimore RS, Tani LY, Sable CA, Shulman ST, et al. Revision of the Jones Criteria for the diagnosis of acute rheumatic fever in the era of Doppler echocardiography: a scientific statement from the American Heart Association. Circulation. 2015 May 19. 131 (20):1806-18. [Medline]. [Full Text].

  12. Irlam JH, Mayosi BM, Engel ME, Gaziano TA. A cost-effective strategy for primary prevention of acute rheumatic fever and rheumatic heart disease in children with pharyngitis. S Afr Med J. 2013 Sep 3. 103(12):894-5. [Medline].

  13. Fine AM, Nizet V, Mandl KD. Participatory medicine: a home score for streptococcal pharyngitis enabled by real-time biosurveillance: a cohort study. Ann Intern Med. 2013 Nov 5. 159(9):577-83. [Medline].

  14. Lennon D, Stewart J, Anderson P. Primary Prevention of Rheumatic Fever. Pediatr Infect Dis J. 2016 Jul. 35 (7):820. [Medline].

  15. [Guideline] Gerber MA, Baltimore RS, Eaton CB, Gewitz M, Rowley AH, Shulman ST, et al. Prevention of rheumatic fever and diagnosis and treatment of acute Streptococcal pharyngitis: a scientific statement from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee of the Council on Cardiovascular Disease in the Young, the Interdisciplinary Council on Functional Genomics and Translational Biology, and the Interdisciplinary Council on Quality of Care and Outcomes Research: endorsed by the American Academy of Pediatrics. Circulation. 2009 Mar 24. 119(11):1541-51. [Medline].

  16. He VY, Condon JR, Ralph AP, Zhao Y, Roberts K, de Dassel JL, et al. Long Term Outcomes from Acute Rheumatic Fever and Rheumatic Heart Disease: A Data-Linkage and Survival Analysis Approach. Circulation. 2016 Jul 12. [Medline].

  17. Bryant PA, Robins-Browne R, Carapetis JR, Curtis N. Some of the people, some of the time: susceptibility to acute rheumatic fever. Circulation. 2009 Feb 10. 119(5):742-53. [Medline].

  18. Carapetis JR, Brown A, Wilson NJ, Edwards KN, Rheumatic Fever Guidelines Writing Group. An Australian guideline for rheumatic fever and rheumatic heart disease: an abridged outline. Med J Aust. 2007 Jun 4. 186(11):581-6. [Medline].

  19. Erdem G, Mizumoto C, Esaki D, Reddy V, Kurahara D, Yamaga K. Group A streptococcal isolates temporally associated with acute rheumatic fever in Hawaii: differences from the continental United States. Clin Infect Dis. 2007 Aug 1. 45(3):e20-4. [Medline].

  20. Gibofsky A, Kerwar S, Zabriskie JB. Rheumatic fever. The relationships between host, microbe, and genetics. Rheum Dis Clin North Am. 1998 May. 24(2):237-59. [Medline].

  21. Guzman, L. Rheumatic Fever. Klippel J, ed. Primer on the Rheumatic Diseases. 11th ed. Atlanta, Ga: Arthritis Foundation; 1997. 168-71.

  22. Gündogdu F, Islamoglu Y, Pirim I, Gurlertop Y, Dogan H, Arslan S. Human leukocyte antigen (HLA) class I and II alleles in Turkish patients with rheumatic heart disease. J Heart Valve Dis. 2007 May. 16(3):293-9. [Medline].

  23. Kaplan EL. Pathogenesis of acute rheumatic fever and rheumatic heart disease: evasive after half a century of clinical, epidemiological, and laboratory investigation. Heart. 2005 Jan. 91(1):3-4. [Medline].

  24. McLean A, Waters M, Spencer E, Hadfield C. Experience with cardiac valve operations in Cape York Peninsula and the Torres Strait Islands, Australia. Med J Aust. 2007 Jun 4. 186(11):560-3. [Medline].

  25. Minola E, Arosio M, Rizzo G, et al. Clinical and laboratory features of acute rheumatic fever: a 18-year experience. Infez Med. 2005. 13(1):28-32. [Medline].

  26. Soudarssanane MB, Karthigeyan M, Mahalakshmy T, Sahai A, Srinivasan S, Subba Rao KS. Rheumatic fever and rheumatic heart disease: primary prevention is the cost effective option. Indian J Pediatr. 2007 Jun. 74(6):567-70. [Medline].

  27. Stanevicha V, Eglite J, Zavadska D, Sochnevs A, Shantere R, Gardovska D. HLA Class II DR and DQ genotypes and haplotypes associated with rheumatic fever among clinically homogenous patients in children in Latvia. Arthritis Res Ther. 2007 Jun 10. 9(3):R58. [Medline].

  28. Weidebach W, Goldberg AC, Chiarella JM, et al. HLA class II antigens in rheumatic fever. Analysis of the DR locus by restriction fragment-length polymorphism and oligotyping. Hum Immunol. 1994 Aug. 40(4):253-8. [Medline].

  29. Zakkar M, Amirak E, Chan KM, Punjabi PP. Rheumatic mitral valve disease: current surgical status. Prog Cardiovasc Dis. 2009 May-Jun. 51(6):478-81. [Medline].

 
Previous
Next
 
Clinical manifestations and time course of acute rheumatic fever.
Chest radiograph showing cardiomegaly due to carditis of acute rheumatic fever.
Erythema marginatum, the characteristic rash of acute rheumatic fever.
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.